Vellgus Red Light Team

Bottom line: Red light therapy (also called low-level light therapy or LLLT) is an emerging, non-invasive adjunct for managing styes and the underlying meibomian gland dysfunction that often drives recurrence. While the evidence base is smaller than for warm compresses…

Bottom line: Red light therapy (photobiomodulation) is an emerging, non-invasive adjunctive treatment for dry eye syndrome, particularly when driven by meibomian gland dysfunction (MGD) and ocular surface inflammation. Early clinical evidence shows measurable improvements in symptom scores and tear film…

Bottom line: Red light therapy—most often delivered as part of low-level light therapy (LLLT) alongside blue light—is not a standalone cure for blepharitis. However, peer-reviewed clinical data published in 2025 demonstrate that combined red and blue LLLT, particularly when paired…

Bottom line up front: Red light therapy is not a primary treatment for conjunctivitis. The peer-reviewed evidence for light-based therapy in ocular inflammation is narrow, condition-specific, and still largely preclinical for conjunctivitis. However, a distinct form of infrared light—water-filtered infrared…

Diabetic retinopathy remains a leading cause of preventable blindness in working-age adults, and patients are increasingly asking whether red light therapy—photobiomodulation—can help. The short answer: the science is promising but not yet definitive. High-quality randomized evidence in humans is limited,…

Bottom line: Red light therapy—clinically termed photobiomodulation (PBM)—has moved from speculative biohacking to a regulated medical procedure for a specific subset of dry age-related macular degeneration (AMD) patients. The FDA authorized the Valeda Light Delivery System in late 2024 based…

Bottom line up front: Red light therapy for glaucoma is an investigational neuroprotection strategy with plausible biological mechanisms and encouraging animal data—but zero published human trials demonstrating that it preserves vision or slows glaucoma progression. It does not lower intraocular…

Presbyopia affects nearly everyone over 40, yet treatment options remain largely compensatory—glasses, contacts, or surgery—rather than restorative. A 2026 randomized controlled trial from Hong Kong Polytechnic University is now testing whether repeated low-level red light therapy (RLRL) can change that…

Bottom line: Red light therapy does not treat, correct, or reverse astigmatism. Astigmatism is a structural refractive error caused by the shape of your cornea or lens. Red light therapy cannot reshape those tissues. However, a growing body of research…

Red light therapy is not an approved cure for hyperopia, but emerging evidence suggests a specific, medically supervised application: accelerating axial elongation in hyperopic children to support emmetropization. This distinction matters. The same photobiomodulation mechanism that has made red light…